Drug Profile
Research programme: eye disorder therapeutics - Altheos
Alternative Names: AK 138; AK 138 series; ATS8535Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Asahi Kasei Pharma Corp
- Developer Altheos
- Class
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma; Ocular hypertension
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic, Drops)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ocular-hypertension in USA (Ophthalmic, Drops)
- 10 Feb 2012 Preclinical development is ongoing in USA